![]() Ardelyx Ardelyx develops novel oral therapeutics to treat mineral metabolism and metabolic disorders. | ||
Founding Date | Founding Date 2014 | Founding Date 2007 |
Type | Type Private | Type Public |
Tags | ||
Locations | Locations Oxford, GB HQ Cambridge, GB Cambridge, US | Locations Fremont, US HQ Waltham, US Waltham, US |
Employees | Employees 1804% increase | Employees 882% increase |
Financial | ||
Revenue (est.) | Revenue (est.) £2.8m (FY, 2019) | Revenue (est.) $407.3m (FY, 2025) |
Net income | Net income (£2.5m) (FY, 2019) | Net income ($61.6m) (FY, 2025) |
Funding | ||
Total funding raised | Total funding raised $ 61.9m | Total funding raised $ 61.1m |

Ardelyx develops novel oral therapeutics to treat mineral metabolism and metabolic disorders.
View company